Altimmune’s (ALT) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $12.00 price ...
Rezolute’s (RZLT) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Rezolute (NASDAQ:RZLT – Free Report) in a report published on Wednesday morning,Benzinga reports. The firm currently has a $14.00 price objective ...
Hosted on MSN1d
HC Wainwright & Co. Initiates Coverage of Vertical Aerospace (EVTL) with Buy Recommendation
Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy ...
H.C. Wainwright maintains $80 target on Corcept Therapeutics stock
H.C. Wainwright reiterated its Buy rating and $80.00 price target for Corcept Therapeutics (NASDAQ:CORT), highlighting the company's consistent growth in Korlym sales over the past eight quarters ...
Neurocrine price target lowered to $185 from $190 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...
Vertical Aerospace initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Vertical Aerospace (EVTL) with a Buy rating and $12 price target The company specializes in designing ...
H.C. Wainwright Raises BlackSky Technology Inc. (BKSY) Price Target to $20, Maintains ‘Buy’ Amid Strong Contract Growth
We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...
Joplin Globe9d
H.C. Wainwright Initiates Coverage on Knightscope (NASDAQ: KSCP) with a Buy Rating and $16 Price Target
(NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has initiated coverage on the company with a Buy ...
Investing18d
H.C. Wainwright Reiterates Buy Rating on Axsome Shares
On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data, this ...